Found: 10
Select item for more details and to access through your institution.
The presence of the Rb c-box peptide in the cytoplasm inhibits p210<sup>bcr-abl</sup> transforming function.
- Published in:
- Oncogene, 1999, v. 18, n. 8, p. 1589, doi. 10.1038/sj.onc.1202479
- By:
- Publication type:
- Article
Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210<sup>bcr–abl</sup> positive 32D myeloid leukemia cells.
- Published in:
- Oncogene, 1998, v. 17, n. 7, p. 825, doi. 10.1038/sj.onc.1201999
- By:
- Publication type:
- Article
Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.
- Published in:
- Journal of Oncology Pharmacy Practice, 2012, v. 18, n. 1, p. 17, doi. 10.1177/1078155210392616
- By:
- Publication type:
- Article
Survival outcomes of allogeneic hematopoietic cell transplants with EBV‐positive or EBV‐negative post‐transplant lymphoproliferative disorder, A CIBMTR study.
- Published in:
- Transplant Infectious Disease, 2019, v. 21, n. 5, p. N.PAG, doi. 10.1111/tid.13145
- By:
- Publication type:
- Article
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.
- Published in:
- Journal of Oncology Pharmacy Practice, 2023, v. 29, n. 1, p. 45, doi. 10.1177/10781552211052635
- By:
- Publication type:
- Article
Treatment of Acquired von Willebrand Syndrome and Prevention of Bleeding Postautologous Stem Cell Transplant during Severe Pancytopenia with IVIG.
- Published in:
- Case Reports in Hematology, 2015, v. 2015, p. 1, doi. 10.1155/2015/809313
- By:
- Publication type:
- Article
Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
- Published in:
- British Journal of Haematology, 1998, v. 103, n. 3, p. 678, doi. 10.1046/j.1365-2141.1998.01048.x
- By:
- Publication type:
- Article
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
- Published in:
- British Journal of Haematology, 1997, v. 96, n. 2, p. 328, doi. 10.1046/j.1365-2141.1997.d01-2012.x
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Phase I and Pharmacokinetic Study of Once-Daily Dosing of Intravenously Administered Busulfan in the Setting of a Reduced- Intensity Preparative Regimen and Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Renal Cell Carcinoma.
- Published in:
- Military Medicine, 2006, v. 171, n. 2, p. 161, doi. 10.7205/MILMED.171.2.161
- By:
- Publication type:
- Article